Plasma reactive carbonyl species levels and risk of non-alcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 6, 2011, Pages 1010-1015

  Liu, Shenglin ^a   Shi, Wang ^a   Li, Guolin ^a   Jin, Bo ^a   Chen, Yaqin ^a   Hu, Hui ^a   Liu, Li ^a   Xie, Fuxia ^a   Chen, Keke ^a   Yin, Dazhong ^a  

^a HUNAN NORMAL UNIVERSITY   (China)

Author keywords

Non alcoholic fatty liver disease; Oxidative stress; Reactive carbonyl species

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; GLUCOSE; MALONALDEHYDE; OXIDIZING AGENT; REACTIVE CARBONYL SPECIES; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; BODY MASS; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79955925213     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06672.x     Document Type: Article

References (45)

1. Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 2009; 50: 204-10.
2. Tominaga K, Kurata JH, Chen YK etal. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig. Dis. Sci. 1995; 40: 2002-9.
3. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
4. Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J. Gastroenterol. 2009; 15: 6017-22.
5. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-31.
6. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 2010; 5: 145-71.
7. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J. Hepatol. 2008; 49: 600-7.
8. Mendes FD, Suzuki A, Angulo P. Prevalence and indicators of portal hypertension in nonalcoholic fatty liver disease. Gastroenterology 2004; 126: A759.
9. Fallo F, Dalla Pozza A, Sonino N etal. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 2009; 19: 646-53.
10. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 363: 1341-50.
11. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104.
12. Promrat K, Kleiner DE, Niemeier HM etal. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010; 51: 121-9.
13. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-8.
14. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83.
15. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-8.
16. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
17. Day CP. Pathogenesis of steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 2002; 16: 663-78.
18. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin. Liver Dis. 2008; 28: 370-9.
19. Roskams T, Yang SQ, Koteish A etal. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. Am. J. Pathol. 2003; 163: 1301-11.
20. Sanyal AJ, Campbell-Sargent C, Mirshahi F etal. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
21. Patrick L. Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Altern. Med. Rev. 2002; 7: 276-91.
22. Das KS, Balakrishnan V, Mukherjee S, Vasudevan DM. Evaluation of blood oxidative stress-related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. Scand. J. Clin. Lab. Invest. 2008; 68: 323-34.
23. Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J. Hepatol. 2005; 42: 585-91.
24. Videla LA, Rodrigo R, Orellana M etal. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. (Lond) 2004; 106: 261-8.
25. Loguercio C, De Girolamo V, de Sio I etal. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J. Hepatol. 2001; 35: 568-74.
26. Turgeon ML. Principles of blood collection. In: Turgeon ML, ed. Clinical Hematology: Theory and Procedures, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2004; 18-40.
27. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
28. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
29. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998; 15: 539-53.
30. Siest G, Schiele F, Galteau M-M etal. Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin. Chem. 1975; 21: 1077-87.
31. Zeng MD, Fan JG, Lu LG etal. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver diseases. J. Dig. Dis. 2008; 9: 108-12.
32. Chan HL, de Silva HJ, Leung NW, Lim SG, Farrell GC. How should we manage patients with non-alcoholic fatty liver disease in 2007? J. Gastroenterol. Hepatol. 2007; 22: 801-8.
33. Li G, He H, Yan H, Zhao Q, Yin D. Does carbonyl stress cause increased blood viscosity during storage? Clin. Hemorheol. Microcirc. 2010; 44: 145-54.
34. Grubbs F. Procedures for detecting outlying observations in samples. Technometrics 1969; 11: 1-21.
35. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. New York: Wiley, 2000.
36. Gil L, Siems W, Mazurek B etal. Age-associated analysis of oxidative stress parameters in human plasma and erythrocytes. Free Radic. Res. 2006; 40: 495-505.
37. Kadiiska MB, Gladen BC, Baird DD etal. Biomarkers of oxidative stress study II. Are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic. Biol. Med. 2005; 38: 698-710.
38. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic. Biol. Med. 1990; 9: 515-40.
39. Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): S186-90.
40. Yin DZ, Chen KJ. The essential mechanisms of aging: irreparable damage accumulation of biochemical side-reactions. Exp. Gerontol. 2005; 40: 455-65.
41. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol. Med. 2006; 12: 555-8.
42. Xu Z, Chen L, Leung L, Yen TS, Lee C, Chan JY. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc. Natl. Acad. Sci. U.S.A. 2005; 102: 4120-5.
43. Uchiyama S, Shimizu T, Shirasawa T. CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J. Biol. Chem. 2006; 281: 31713-19.
44. Aldini G, Dalle-Donne I, Colombo R, Maffei Facino R, Milzani A, Carini M. Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. ChemMedChem 2006; 1: 1045-58.
45. Levine RL, Stadtman ER. Carbonylated proteins and their implication in physiology and pathology. In: Desiderio DM, Nibbering NM, eds. Redox Proteomics: From Protein Modifications to Cellular Dysfunction and Diseases. NJ: John Wiley & Sons, Inc, 2006; 123-68.